In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.
about
Trans-activation of HIV-1 LTR-directed gene expression by tat requires protein kinase CRole of SP1-binding domains in in vivo transcriptional regulation of the human immunodeficiency virus type 1 long terminal repeatIdentification and purification of a human immunoglobulin-enhancer-binding protein (NF-kappa B) that activates transcription from a human immunodeficiency virus type 1 promoter in vitroTNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors.Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein.NF-kappa B protein purification from bovine spleen: nucleotide stimulation and binding site specificityRepeated B motifs in the human immunodeficiency virus type I long terminal repeat enhancer region do not exhibit cooperative factor binding.Hepatitis B virus X gene can transactivate heterologous viral sequences.Identification of c-fos-responsive elements downstream of TAR in the long terminal repeat of human immunodeficiency virus type-1.Nuclear factors that bind two regions important to transcriptional activity of the simian immunodeficiency virus long terminal repeatHepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1.Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat.Identification of cellular proteins that bind to the human immunodeficiency virus type 1 trans-activation-responsive TAR element RNAIdentification of transcriptional suppressor proteins that bind to the negative regulatory element of the human immunodeficiency virus type 1kappa B elements strongly activate gene expression in non-lymphoid cells and function synergistically with NF1 elements.Negative regulation of human immune deficiency virus replication in monocytes. Distinctions between restricted and latent expression in THP-1 cells.Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription fVariable role of the long terminal repeat Sp1-binding sites in human immunodeficiency virus replication in T lymphocytes.Linker-scanning mutational analysis of the transcriptional activity of the human immunodeficiency virus type 1 long terminal repeatRapid activation and subsequent down-regulation of the human immunodeficiency virus type 1 promoter in the presence of Tat: possible mechanisms contributing to latency.A single amino acid change in CUP2 alters its mode of DNA bindingStimulation of the human immunodeficiency virus type 1 enhancer by the human T-cell leukemia virus type I tax gene product involves the action of inducible cellular proteinsUV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein.cis-acting elements in the U3 region of a simian immunodeficiency virus.Multiple transcriptional regulatory domains in the human immunodeficiency virus type 1 long terminal repeat are involved in basal and E1A/E1B-induced promoter activity.The NF-kappa B binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity.Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequenceSilencing of human immunodeficiency virus long terminal repeat expression by an adenovirus E1a mutant.Interaction of enhancer-binding protein EBP1 (NF-kappa B) with the human immunodeficiency virus type 1 enhancer.Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat.Human immunodeficiency virus type 1 Tat-mediated trans activation correlates with the phosphorylation state of a cellular TAR RNA stem-binding factor.A novel cis-acting element that controls transcription of human immunodeficiency virus type 1 DNA, depending on cell type.Identification of a region within the human immunodeficiency virus type 1 long terminal repeat that is essential for transactivation by the hepatitis B virus gene X.UV-induced transcription from the human immunodeficiency virus type 1 (HIV-1) long terminal repeat and UV-induced secretion of an extracellular factor that induces HIV-1 transcription in nonirradiated cells.USF-related transcription factor, HIV-TF1, stimulates transcription of human immunodeficiency virus-1.Ubiquitous and lymphocyte-specific factors are involved in the induction of the mouse interleukin 2 gene in T lymphocytesAn in vitro transcription analysis of early responses of the human immunodeficiency virus type 1 long terminal repeat to different transcriptional activators.Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1.Analysis of the human immunodeficiency virus long terminal repeat by in vitro transcription competition and linker scanning mutagenesis.
P2860
Q24556556-4807434F-FFA6-42F7-A472-392F00F6CA75Q24645992-68C1C49A-9223-4736-924D-15C8BEA26BDCQ33584734-1094E344-4A84-42F0-86A7-6AD47F63FBC1Q33609443-7A577548-4B11-4F97-85F4-281859C25C24Q33666097-84335C32-677A-41C6-98C8-41FEED421607Q33676218-97CB7195-3239-4E86-93EC-9F2CEAB6CA1CQ33684251-041B557F-C374-4807-8CAB-BACCA682AC66Q33845263-BF39BA8F-4429-4FA9-8B98-616854EF70C4Q33902078-5557FC40-8EA0-4599-90C9-0EE45E8D2817Q33934527-A9A15CBC-51F4-4A03-AD19-C74F055F2212Q34288246-1FDC399F-7D0F-4559-9862-0DA99E7CF201Q34295016-83F40597-6629-4758-8FAA-3BCA32D3C892Q34311433-503214FE-1D4F-4F0A-A372-F699016D7B85Q35792284-B68DFEA1-474E-4399-802F-2867D28B65B0Q35951032-59DFE468-1310-4258-9DFB-6531087D6E07Q36351087-411566B2-0F83-4528-A02A-B0CDF6879095Q36633683-712786E4-727C-4F2D-8E6D-248B6CBCE6B6Q36682395-FAAE3393-F1ED-4B23-8BE1-9D66BCE36376Q36688898-61386AA3-53CF-4F19-B4A0-D543E815180DQ36694541-057AC000-357B-4985-8B69-208F228C56F3Q36724512-81A4FF84-6C2E-4C45-92E6-8404F16E9E89Q36791571-306A16AA-BD5A-40EE-A1AC-8E791D7AD6F4Q36796267-0870CAC5-4D08-41F9-980A-5D0A76C9DAA9Q36808930-C6EF5DC4-4423-492A-9318-5D7889DB3F15Q36831514-B44963A1-D0D3-4565-8EDB-F3097FCE5F86Q36831819-0F279E8C-350B-4537-B9C2-D814A6FD9A65Q36881679-0B15EAC4-E73A-4BAA-8589-F7F243659FF7Q37694247-6C789FC1-4EB6-4795-BF74-CD174F0B77FFQ38341650-73E57716-08C2-4E47-8858-BAC2CB235C10Q38346354-4D4F751A-5945-42E2-B506-CC2C4A7D47AAQ40066208-9092B13F-74FA-4593-9615-76B5BFDDC0C0Q40113669-224B21EF-64D3-4F9A-B4C4-BCEC6FD70904Q40115896-83F09BE1-4E0F-4973-91A9-1E292CC1F8A1Q40117307-E8DB575F-66D6-4EA1-8062-470B34C63E18Q40506561-AB4FEE9D-B9A6-4BBA-8A34-418B018AAE15Q40817161-6413E539-E974-4EDE-8609-BB24E2371E56Q41688788-4EF77DDC-B262-4922-97D4-C0059FBF6BA2Q42735234-44138E69-172F-4197-A38B-070BCBC187A2Q45856643-51FEA752-BEB4-4878-A396-FD6A6664C1F7
P2860
In vitro activation of the HIV-1 enhancer in extracts from cells treated with a phorbol ester tumor promoter.
description
1987 nî lūn-bûn
@nan
1987 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@ast
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@en
type
label
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@ast
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@en
prefLabel
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@ast
In vitro activation of the HIV ...... phorbol ester tumor promoter.
@en
P2093
P2860
P1433
P1476
In vitro activation of the HIV ...... a phorbol ester tumor promoter
@en
P2093
P2860
P304
P356
10.1002/J.1460-2075.1987.TB02752.X
P407
P577
1987-12-01T00:00:00Z